2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Drug-Linker Conjugates for ADC Isoform

Drug-Linker Conjugates for ADC

 

Drug-Linker Conjugates for ADC Related Products (121):

Cat. No. Product Name Effect Purity
  • HY-131057
    Mc-VC-PAB-SN38
    		98.02%
    Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-139441
    DM21
    		99.92%
    DM21 is a conjugate of a cleavable ADC agent and a linker (ADC linker) used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-126687
    Mal-PEG4-VC-PAB-DMEA-PNU-159682
    Mal-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker Mal-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682.
  • HY-136170
    MC-SN38
    		98.65%
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks.
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
    		99.82%
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
  • HY-157544
    PC5-VC-PAB-MMAE
    		99.76%
    PC5-VC-PAB-MMAE consists the ADCs linker (PC5-VC-PAB) and potent tubulin inhibitor (MMAE). PC5-VC-PAB-MMAE is a agent-linker conjugate for ADC.
  • HY-19813A
    mDPR-Val-Cit-PAB-MMAE TFA
    		99.51%
    mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1].
  • HY-153892
    Gly-Mal-GGFG-Deruxtecan 2-hydroxypropanamide
    		99.68%
    Gly-Mal-GGFG-Deruxtecan 2-hydroxy propionamide is a camptothecin-deriver and can be used as a drug linker for ADC.
  • HY-153180
    PB038
    PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
  • HY-130812
    Gemcitabine-O-Si(di-iso)-O-Mc
    		98.79%
    Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker.
  • HY-148426
    OSu-PEG4-VC-PAB-MMAE
    OSu-PEG4-VC-PAB-MMAE involves in GDP-FAmP4MMAE (Monomethylauristatin E) synthesis, which is for GDP label via site-specific conjugation.
  • HY-104025
    SPB
    		98.20%
    SPB is a agent-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.
  • HY-101152
    SG3199-Val-Ala-PAB
    SG3199-Val-Ala-PAB is an intermediate of Tesirine synthesis. Tesirine is a agent-linker conjugate for ADC which can be used for the research of several cancers.
  • HY-132250
    MCC-DM1
    		99.72%
    MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues.
  • HY-148820
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
    		98.43%
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make antibody agent conjugate (ADC).
  • HY-148346A
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA
    		98.20%
    STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer.
  • HY-153013
    SN38-COOH
    		98.85%
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis.
  • HY-148057
    TCO-PEG4-VC-PAB-MMAE
    		99.30%
    TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
  • HY-156755
    Propargyl-PEG4-GGFG-DXd
    		99.99%
    Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate for ADC. Propargyl-PEG4-GGFG-DXd contains a ADC linker and a DNA topoisomerase I inhibitor DXd (HY-13631D).
  • HY-128979
    Deruxtecan analog 2
    		99.48%
    Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.